573 related articles for article (PubMed ID: 11085540)
1. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
[TBL] [Abstract][Full Text] [Related]
2. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 2 induces differentiation and apoptosis of Askin tumour cells.
Kim MS; Kim CJ; Jung HS; Seo MR; Juhnn YS; Shin HY; Ahn HS; Thiele CJ; Chi JG
J Pathol; 2004 Jan; 202(1):103-12. PubMed ID: 14694527
[TBL] [Abstract][Full Text] [Related]
4. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
5. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
7. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
8. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
[TBL] [Abstract][Full Text] [Related]
9. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
[TBL] [Abstract][Full Text] [Related]
11. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract][Full Text] [Related]
12. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G
Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
Kontny HU; Hämmerle K; Klein R; Shayan P; Mackall CL; Niemeyer CM
Cell Death Differ; 2001 May; 8(5):506-14. PubMed ID: 11423911
[TBL] [Abstract][Full Text] [Related]
14. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Merchant MS; Yang X; Melchionda F; Romero M; Klein R; Thiele CJ; Tsokos M; Kontny HU; Mackall CL
Cancer Res; 2004 Nov; 64(22):8349-56. PubMed ID: 15548704
[TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor (bFGF)-induced cell death is mediated through a caspase-dependent and p53-independent cell death receptor pathway.
Westwood G; Dibling BC; Cuthbert-Heavens D; Burchill SA
Oncogene; 2002 Jan; 21(5):809-24. PubMed ID: 11850809
[TBL] [Abstract][Full Text] [Related]
16. Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells.
Lollini PL; Landuzzi L; Frabetti F; Rossi I; Nicoletti G; Scotlandi K; Serra M; Baldini N; De Giovanni C; Nanni P
Clin Cancer Res; 1998 Aug; 4(8):1843-9. PubMed ID: 9717810
[TBL] [Abstract][Full Text] [Related]
17. Ewing's sarcoma/peripheral primitive neuroectodermal tumor (ES/PNET) differentiation in endometrial serous carcinomas.
Quddus MR; Rashid L; Sung CJ; Steinhoff MM; Cunxian Zhang ; Lawrence WD
Reprod Sci; 2009 Jun; 16(6):591-5. PubMed ID: 19318687
[TBL] [Abstract][Full Text] [Related]
18. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
Sancéau J; Poupon MF; Delattre O; Sastre-Garau X; Wietzerbin J
Oncogene; 2002 Oct; 21(50):7700-9. PubMed ID: 12400012
[TBL] [Abstract][Full Text] [Related]
19. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]